Belief BioMed and Takeda China Announced Exclusive Commercial Partnership in the Field of Hemophilia B，Bringing Innovative Gene Therapy to Chinese Patients

Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901

Belief BioMed’s Second AAV-based Gene Therapy Drug Candidate was Granted Orphan Drug Designation by the FDA

The Case Report of Belief BioMed’s Hemophilia B Gene Therapy Drug Candidate BBM-H901 Published in The New England Journal of Medicine

Belief BioMed’s AAV-based Gene Therapy Drug Candidate Receives China CDE’s Breakthrough Therapy Designation

Belief BioMed’s AAV-based Gene Therapy Drug Candidate was Granted Orphan Drug Designation by the FDA

Belief BioMed Co-Founder and CEO Dr. Jane Zheng was Selected by Forbes as One of the "50 Chinese Women in Science and Technology"!

Clinical Trial Results of Belief BioMed's Hemophilia B Gene Therapy Drug Candidate BBM-H901 Published in The Lancet Haematology

Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B

Remarkable success once more! Belief BioMed won the award of "the 10th China Innovation and Entrepreneurship Competition Excellent Enterprise"

2021 Future Medical Industry Summit, Dr. Xiao Xiao【Gene Therapy: Expansion from Rare Disease to Common Medicine】

Belief Biomed’s Gene Therapy for Hemophilia B Receives NMPA IND Approval: First Intravenous Infusion Gene Therapy for Rare Disease in China

Belief BioMed and China Chord Rare Disease Center held a meeting in Minhang, Shanghai

Belief BioMed announced the opening of new development & manufacturing center in Minhang Shanghai

Belief BioMed seized the new developing opportunity of Lin-gang and signed a contract to construct the key project in Lin-gang Biotechnology Industrial Park

The 8th China Rare Disease Summit

Belief BioMed Invests Over 100 million RMB to Construct a State-Of-The-Art Gene Therapy Manufacturing plant in Minhang Shanghai.